Severity of Illness Index
"Severity of Illness Index" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Levels of severity of illness within a diagnostic group which are established by various measurement criteria.
Severity of Illness Index
- Severity of Illness Index
- Illness Index Severities
- Illness Index Severity
- Index Severities, Illness
- Index Severity, Illness
Below are MeSH descriptors whose meaning is more general than "Severity of Illness Index".
Below are MeSH descriptors whose meaning is more specific than "Severity of Illness Index".
This graph shows the total number of publications written about "Severity of Illness Index" by people in Harvard Catalyst Profiles by year, and whether "Severity of Illness Index" was a major or minor topic of these publication.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
Below are the most recent publications written about "Severity of Illness Index" by people in Profiles.
Rates of malignancies among patients with moderate to severe atopic dermatitis: a retrospective cohort study. BMJ Open. 2023 03 10; 13(3):e071172.
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study. Expert Rev Pharmacoecon Outcomes Res. 2023 Apr; 23(4):419-430.
AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis. Gastroenterology. 2023 03; 164(3):344-372.
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br J Dermatol. 2023 Jan 23; 188(1):22-31.
Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exception policy and outcomes in pediatric patients with hepatopulmonary syndrome requiring liver transplantation. Liver Transpl. 2023 Feb 01; 29(2):134-144.
Diffusing Capacity and Mortality in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2023 01; 20(1):38-46.
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis. Arthritis Res Ther. 2022 12 28; 24(1):283.
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. 2022 12 23; 12(12):e063650.
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatr Drugs. 2023 Jan; 25(1):67-77.
Development and Validation of the TUMMY-UC: A Patient-Reported Outcome for Pediatric Ulcerative Colitis. Gastroenterology. 2023 04; 164(4):610-618.e4.